Skip to main content
Signal8
Launch Terminal

Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

NASDAQ:VERAHealthcare
+1.47%$30.98
AH$30.37-1.97%vs close
Mkt Cap$2.23B
Float63.21M
O/S72.06M
Vol
$ Vol
RVOL
Inst Own-
SI21.5%
Earnings
Dilution
Vera Therapeutics, Inc. logoNASDAQ:VERA$30.98+1.47%
Upcoming Catalysts
Phase Distribution
6 lead-sponsored trials·4 active·1 completed
Phase 24
Phase 32

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Active, not recruiting

    Atacicept in Subjects With IgA Nephropathy

    Atacicept

    IgA Nephropathy, Berger Disease

    Enrollment
    428
    Start
    Jun 2023
    Primary Completion
    May 2025
    Completion
    Jul 2028est.
    NCT04716231
  • Phase 3
    Withdrawn

    Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

    Atacicept, Placebo

    Lupus Nephritis (LN)

    Enrollment
    0
    Start
    Nov 2022
    Primary Completion
    Mar 2026est.
    Completion
    Dec 2028est.
    NCT05609812
  • Phase 2
    Completed

    A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

    MAU868

    BK Virus Infection

    Enrollment
    30
    Start
    Aug 2020
    Primary Completion
    Feb 2022
    Completion
    Feb 2022
    NCT04294472
  • Phase 2
    Enrolling by invitation

    A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

    Atacicept 150 mg

    IgA Nephropathy (IgAN), Renal and Urinary Disorders +1

    Enrollment
    750
    Start
    Dec 2024
    Primary Completion
    May 2031est.
    Completion
    May 2031est.
    NCT06674577
  • Phase 2
    Recruiting

    Atacicept in Multiple Glomerular Diseases

    Atacicept

    pMN, IgAN +3

    Enrollment
    250
    Start
    Jul 2025
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2027est.
    NCT06983028
  • Phase 2
    Active, not recruiting

    Monthly Dosing of Atacicept in IgAN

    Atacicept

    IgA Nephropathy (IgAN), Berger Disease

    Enrollment
    90
    Start
    May 2025
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2027est.
    NCT07020923
Search ClinicalTrials.gov for “Vera Therapeutics”